AJP - Regu Fuel your research with LabChart
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

Am J Physiol Regul Integr Comp Physiol 278: R1496-R1505, 2000;
0363-6119/00 $5.00
This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow A corrigendum has been published
Right arrow A corrigendum has been published
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via ISI Web of Science (43)
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Takahashi, Y.
Right arrow Articles by Clyman, R. I.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Takahashi, Y.
Right arrow Articles by Clyman, R. I.
Vol. 278, Issue 6, R1496-R1505, June 2000

Cyclooxygenase-2 inhibitors constrict the fetal lamb ductus arteriosus both in vitro and in vivo

Yasushi Takahashi1, Christine Roman1, Sylvain Chemtob3, Mary M. Tse4, Emil Lin4, Michael A. Heymann1,2, and Ronald I. Clyman1,2

1 Cardiovascular Research Institute and Departments of 2 Pediatrics and 4 Pharmacy, University of California, San Francisco, San Francisco, California 94143-0544; and 3 Research Center, Hôpital Sainte-Justine, Montreal, Quebec, Canada H3T IC5


    ABSTRACT
TOP
ABSTRACT
INTRODUCTION
METHODS
RESULTS
DISCUSSION
REFERENCES

Nonselective cyclooxygenase (COX) inhibitors are potent tocolytic agents; however, they also have adverse fetal effects such as constriction of the fetal ductus arteriosus. Recently, selective COX-2 inhibitors have been used in the management of preterm labor in the hope of avoiding fetal complications. However, both COX-1 and -2 are expressed by cells of the ductus arteriosus. We used fetal lambs (0.88 gestation) to assess the ability of selective COX-2 inhibitors celecoxib and NS398 to affect the ductus arteriosus. Both selective COX-2 inhibitors decreased PGE2 and 6ketoPGF1alpha production in vitro; both inhibitors constricted the isolated ductus in vitro. The nonselective COX-1/COX-2 inhibitor indomethacin produced a further reduction in PG release and an additional increase in ductus tension in vitro. We used a prodrug of celecoxib to achieve 1.4 ± 0.6 µg/ml, mean ± standard deviation, of the active drug in vivo. This concentration of celecoxib produced both an increase in pressure gradient and resistance across the ductus; celecoxib also decreased fetal plasma concentrations of PGE2 and 6ketoPGF1alpha . Indomethacin (0.7 ± 0.2 µg/ml) produced a significantly greater fall in ductus blood flow than celecoxib and tended to have a greater effect on ductus resistence in vivo. We conclude that caution should be used when recommending COX-2 inhibitors for use in pregnant women, because COX-2 appears to play a significant role in maintaining patency of the fetal ductus arteriosus.

cyclooxygenase; cyclooxygenase-1; cyclooxygenase-2; prostaglandin E2; prostaglandin I2; indomethacin; celecoxib


    INTRODUCTION
TOP
ABSTRACT
INTRODUCTION
METHODS
RESULTS
DISCUSSION
REFERENCES

A PATENT DUCTUS ARTERIOSUS is essential for fetal well-being, because it allows the right ventricular output to bypass the high-resistance pulmonary vascular bed (17). The fetal ductus arteriosus synthesizes two important vasodilatory PGs [PGE2 and prostacyclin (PGI2)] that play a major role in maintaining its patency in utero (4, 8, 29). The enzyme cyclooxygenase (COX) converts arachidonic acid to PGH2, which is then further metabolized to various PGs and thromboxanes. Inhibition of COX inhibits PG production and produces constriction of the ductus arteriosus (27, 25) in utero. With advancing gestation, the fetal ductus becomes more reactive to COX inhibition (10, 37). In some cases, this can lead to right ventricular failure.

COX exists in two isoforms: COX-1 and -2. COX-1 is constitutively expressed by most tissues and seems to be responsible for the majority of PG production in the adult (28). COX-2 is an inducible form of the COX enzyme, which is stimulated by proinflammatory agents (21, 22). In contrast to COX-1, selective inhibition of COX-2 does not seem to be associated with adverse effects on the gastrointestinal tract or blood platelets (2, 14, 15, 33, 34). It has been hypothesized that selective COX-2 inhibitors may have the same anti-inflammatory effects as nonselective COX inhibitors, without their unwanted side effects (36). Celecoxib, a selective COX-2 inhibitor, has been approved recently by the Food and Drug Administration for the treatment of arthritis in humans.

Indomethacin, a nonselective inhibitor of both COX-1 and -2, has been used as a tocolytic agent since the mid-1970's. Unfortunately, it crosses the placenta and causes constriction of the fetal ductus arteriosus (11, 25). Recently, COX-2 has been found to play a significant role in the process of parturition (18). This finding has led some investigators to use selective COX-2 inhibitors in the management of preterm labor (32) in the hope of avoiding fetal complications. Unfortunately, there is limited information about the effects of COX-2 inhibition on the fetus. Although COX-2 is induced by cytokines, it is also constitutively expressed by certain organs during fetal development (16, 18, 31). We have recently shown that both COX-1 and -2 are expressed by cells of the fetal lamb ductus arteriosus; in addition, both COX-1 and -2 contribute to ductus arteriosus PG production in vitro (3). The relative roles of COX-1 and -2 in vivo remain to be addressed. Although nonselective inhibitors of both COX-1 and -2, like indomethacin, constrict the ductus in vivo, it may be that the activity of either isoenzyme is sufficient to maintain ductus patency. For example, fetal knockout mice lacking either COX-1 (20) or -2 (27a) have not been reported to have ductus-related problems in utero.

In the following study, we assessed the ability of selective COX-2 inhibitors celecoxib and NS398 to affect PG production and contractility of the fetal lamb ductus in vitro and in vivo. We compared their effects with the nonselective COX inhibitor indomethacin. We observed that COX-2 plays a significant role in maintaining patency of the fetal ductus arteriosus.


    METHODS
TOP
ABSTRACT
INTRODUCTION
METHODS
RESULTS
DISCUSSION
REFERENCES

In Vivo Studies

Animals and surgical preparation. Thirteen pregnant sheep (mixed Western breed) were studied at 127-131 days gestation (full term is ~145 days). The surgical preparation has been described in detail previously (12). Briefly, under intravenous anesthesia with ketamine hydrochloride (0.2-0.4 mg · kg-1 · min-1) and diazepam (0.001 mg · kg-1 · min-1), a midline laparotomy was performed on the ewe, and the fetus was exposed through a small uterine incision. A skin incision was made after administering local lidocaine anesthesia in the fetal forelimb, and catheters were advanced into the ascending aorta from the brachial artery and into the superior vena cava from the brachial vein. The incision was closed, and a new incision was made over the left chest of the fetus. After opening the pericardium, catheters were inserted directly into the main pulmonary artery and a 4- to 6-mm Doppler flow transducer (Transonic Systems, Ithaca, NY) was placed around the ductus arteriosus. The thoracotomy and fetal skin were closed. A catheter was placed in the amniotic cavity, and the uterine incision was closed after replacing amniotic fluid losses with warm saline and administering antibiotics into the amniotic cavity (penicillin G and gentamicin sulfate). All vascular catheters were sealed with heparin and exteriorized to the left flank of the ewe along with the transducer cable. The laparotomy was closed in layers, and the ewe was returned to the cage for recovery. Antibiotics (penicillin G and gentamicin sulfate) were administered intravenously daily to the ewe and into the amniotic cavity.

An additional 17 pregnant sheep were used to determine the dosing regimen needed to achieve the desired fetal plasma concentrations of indomethacin and celecoxib. These fetuses had placement of the systemic arterial and venous vascular catheter, but no thoracotomy.

Dosing regimen for indomethacin and celecoxib. During the last 40% of human gestation, indomethacin crosses the placenta easily and the maternal/fetal serum ratio is 0.97 ± 0.07 (mean ± SD) (26, 35). After maternal indomethacin therapy, mean maternal indomethacin concentrations of 0.688 ± 0.139 µg/ml (1.9 ± 0.4 × 10-6 M) have been associated with fetal ductus arteriosus constriction (25). This concentration range has also been reported to produce effective closure of the neonatal ductus arteriosus when preterm infants are treated with 0.2 mg/kg indomethacin (1). Therefore, we planned to achieve fetal indomethacin concentrations between 0.5 and 0.8 µg/ml (1.4 and 2.2 × 10-6 M). Indomethacin (Sigma Chemical, St. Louis, MO) was dissolved in 50 mM Tris-HCl (pH 8) and infused into the fetal or maternal vein. Indomethacin was rapidly cleared from the fetal plasma (half-life = 62.5 ± 3.5 min, n = 3) after a bolus dose to the fetus of 1 mg/kg (fetal body weight). Conversely, a 2-mg/kg (maternal body weight) bolus dose to the mother produced low fetal concentrations (maximum concentration <0.08 µg/ml) over the next 4 h. In contrast, continuous infusions of indomethacin into the fetus (10 ml/h; dose 0.1-0.5 mg · kg-1 · h-1) produced a rapid and stable concentration in the fetus (Fig. 1). We chose a fetal dosing rate of 0.2 mg · kg-1 · h-1 (fetal body weight) for subsequent studies because this produced stable fetal concentrations of 0.654 ± 0.240 µg/ml (1.8 ± 0.7 × 10-6 M; Fig. 1).


View larger version (27K):
[in this window]
[in a new window]
  		Fig. 1.   Fetal plasma concentrations of indomethacin. Indomethacin was continuously infused into fetal vein at 0.1 (n = 6), 0.2 (n = 4), or 0.5 mg · kg-1 · h-1 (n = 3; estimated fetal body wt) after a priming dose of 0.1, 0.2, or 0.5 mg/kg, respectively, given over 10 min. Indomethacin also was infused into maternal vein at 1.0 mg · kg-1 · h-1 (maternal weight; n = 5) after a 1.0-mg/kg priming dose. Fetal infusion rate was 10 ml/h; maternal infusion rate was 80 ml/h. A: plasma concentrations at 30 min and 1, 2, 3, and 4 h during the continuous infusion (means ± SD). B: maximum, average, and minimum plasma concentration after first 60 min of each infusion rate.

Celecoxib is a highly selective COX-2 inhibitor. The recommended clinical doses of celecoxib (200 and 400 mg/day) produce significant anti-inflammatory effects in osteoarthritis and rheumatoid arthritis (33). The maximal plasma concentrations (0.7 and 1.4 µg/ml, respectively) produced by these doses do not inhibit COX-1 activity in animal studies (34) or in humans (33). Therefore, we planned to study the behavior of the ductus arteriosus when fetal plasma concentrations were between 0.7 and 1.4 µg/ml. In preliminary trials, intravenous infusions failed to achieve the desired plasma concentration range despite the use of several drug-carrier systems (polyethylene glycol-400, beta -cyclodextrin sulfobutyl ether). Therefore, we used the water-soluble, biologically inactive prodrug of celecoxib, SC309A, which is converted to active celecoxib by fetal plasma esterases (data not shown). In three preliminary studies, we found that continuous intravenous infusions of SC309A (20 and 30 mg · kg-1 · h-1) would produce the desired circulating concentrations of celecoxib (see RESULTS). When the infusion of SC309A was discontinued, the half-life of celecoxib in the fetal plasma was 64 ± 10 min.

Experimental protocol. After a 48-h recovery period, the ewe was placed in a study cage and allowed free access to food and water during the experiment. Blood gases and hemodynamic measurements were collected during a 30-min control period. After this, six fetuses were continuously infused with a "low dose" of SC309A [19 ± 5 mg · kg-1 · h-1 (means ± SD), 10 ml/h, after a priming dose of 19 mg/kg] and seven fetuses with a "high dose" (31 ± 8 mg · kg-1 · h-1, 10 ml/h, after a priming dose of 31 mg/kg) for the next 5 h. Within 14 h of discontinuing the infusion, blood gases and hemodynamic parameters had returned to preinfusion values and celecoxib could no longer be detected in the fetal plasma. Nine of these thirteen fetuses (3 low dose/6 high dose) subsequently received an intravenous infusion of indomethacin (0.18 ± 0.02 mg · kg-1 · h-1, 10 ml/h) after a priming dose of 0.18 mg/kg given over 10 min. This was performed 2 days after the initial SC309A study in an attempt to avoid drug interactions. At the end of the infusion studies, the ewe and fetus were given a lethal dose of pentobarbital sodium followed by bilateral thoracotomy. At necropsy, the fetus was weighed, and catheter and flow transducer placement was confirmed. There were no significant differences between the three groups in fetal weights at necropsy (3.75 ± 0.83 kg, n = 13). The estimated fetal weights used during the experiment were based on standardized fetal sheep growth charts established in our laboratory. The final drug dosages used in the infusions were recalculated for the true weights found at necropsy.

Measurements. Arterial and venous pressures were measured by Statham P23 Db pressure transducers (Statham Instruments, Hato Rey, Puerto Rico). Mean pressures were obtained by electrical integration. Ductus arteriosus blood flow was measured with an ultrasonic flowmeter (Transonic Systems). All hemodynamic variables were continuously recorded on a Gould multichannel electrostatic recorder (Gould, Cleveland, OH). Systemic arterial blood gases and pH were measured on a Corning 158 pH/blood gas analyzer (Corning Medical and Scientific, Medfield, MA). Whole blood lactate and glucose concentrations were measured by a 1500 Sport lactate analyzer and 1500 Sidekick glucose analyzer (Yellow Springs Instruments, Yellow Springs, OH).

Ductus arteriosus resistance was calculated as (mean pulmonary arterial pressure minus mean systemic arterial pressure)/ductus arteriosus blood flow per kilogram.

Indomethacin concentrations were determined from 0.1 ml plasma. The samples, after precipitating plasma proteins with 0.5 ml CH3CN containing an internal standard (Carprofen 0.1 µg/ml), were vortexed and centrifuged, and an aliquot of the supernatant was injected for HPLC analysis into an Altex Ultrasphere Octyl 5-µm (5 cm × 4.6 mm) column using a 40% CH3CN + 0.2% H3PO4 (pH 4) mobile phase and detected at 260-nm wavelength with an ultraviolet detector (24). The linear range of detection was 26-4,000 ng/ml.

Celecoxib concentrations were determined from 0.1 ml of plasma; celecoxib prodrug concentrations were determined from 0.1 ml of a dilution of 0.025 ml sample plasma mixed with 0.350 ml control plasma. Samples were treated with 0.25 ml of 0.2 N phosphoric acid. After the addition of 0.05 ml of an internal standard (0.01 mg/ml in a solution of acetonitrile), the sample was extracted with a solid phase extraction column (IST HCX 130 mg sorbent mass) that was previously conditioned with 2 ml of acetonitrile and 2 ml of water. The column was washed with 2 ml of water. The sample was eluted from the column with 1 ml of 1% ammonium hydroxide in methanol. The eluate was evaporated under nitrogen, resolubilized with 0.2 ml of acetonitrile and 0.01 M sodium acetate (50:50, pH 4.1), and analyzed by HPLC using a 0.39 × 15.00-cm Novapak C-18 column with a C-18 guard column (Waters, Milford, MA). The isocratic mobile phase consisted of acetonitrile and 0.01 M sodium acetate (50:50, pH 4.1). The injection volume of the sample was 0.075 ml. The flow rate was 1 ml/min, and the temperature of the column was room temperature. Fluorescence detection was at 240 nm excitation and 380 nm emission. The assay range was 0.05-10.00 µg/ml.

In Vitro Studies

Nineteen fetal lambs (between 125 and 137 days) were delivered by cesarean section. The ewe was anesthetized with a constant intravenous infusion of ketamine HCl and diazepam throughout the procedure. The fetus was given ketamine HCl (30 mg/kg im) before rapid exsanguination. The ductus arteriosus was dissected free of loose adventitial tissue and divided into 1-mm-wide rings that were placed in separate 10-ml organ baths and kept in a dark room, as we have described previously (7). Throughout the experiment, the rings were suspended between two stainless steel hooks at 38°C in a modified Krebs solution (in mM: 118 NaCl, 4.7 KCl, 2.5 CaCl2, 0.9 MgSO4, 1 KH2PO4, 11.1 glucose, and 23 NaHCO3) equilibrated with 5% CO2 (pH 7.4) balanced with 30% O2-65% N2. The bath solution was changed every 30 min. Isometric responses of circumferential tension were measured by Grass FT03C force transducers (Quincy, MA). Each of the rings was stretched initially to a length that results in a maximal contractile response to increases in oxygen tension (6). The rings were stretched during a 15-min interval in medium equilibrated with fetal PO2 (20-34 mmHg, 0.15-0.26 kPa, starting tension). The bath solution was then bubbled with 30% O2-65% N2-5% CO2 (to a PO2 of 175-200 mmHg, 1.31-1.50 kPa) until the tension reached a new plateau (~90-120 min). Inhibitors of COX [celecoxib (30, 33), indomethacin (19, 23), and NS398 (14, 19)] were then added to the bath solution. The specific COX-2 inhibitors (NS398 and celecoxib) were added in concentrations that were specific for their targeted enzymes (14, 19, 30, 33). In all experiments, we allowed the tension in the rings to reach a new steady-state plateau after a drug addition before another experimental agent was added to the bath. After the addition of all contractile drugs, potassium Krebs solution (containing 100 mM KCl substituted for an equimolar amount of NaCl) was used to measure the maximal tension and sodium nitroprusside (10-4 M) was used to determine the minimal tension that could be developed by the ductus.

The difference in tensions between the maximal and minimal tension was considered the net active tension developed by the ring. The difference in tensions between the steady-state tension achieved in 30% oxygen and that at minimal tension was considered the O2 tension. The difference in tensions between the COX inhibitor-induced tension and the steady-state tension achieved in 30% oxygen was considered the COX-inhibitor tension. Changes in tension for each experimental condition were expressed as a percentage of net active tension. The net active tension was always greater than the difference in tension between the maximal tension and the starting tension by 12 ± 9% (P < 0.01, n = 32 rings). This indicates that the ductus rings were actively contracting even at the time of their initial mounting in the organ bath.

In some experiments, PG production by the rings of ductus arteriosus was measured. For these experiments, the bath solution was changed every 40 min. The rings were exposed to two changes of bath solution for each experimental condition. The second change in bath solution was collected for PGE2 or 6 keto PG F1alpha (6ketoPGF1alpha ) analysis [see PGE2 and 6ketoPGF1alpha (PGI2 Metabolite) Radioimmunoassay]. After the experiment, the rings were removed from the baths, blotted dry, and their wet weights determined.

PGE2 and 6ketoPGF1alpha (PGI2 Metabolite) Radioimmunoassay

To determine the amount of PGE2 and 6ketoPGF1alpha (the stable metabolite of PGI2), samples of bath solution or plasma were acidified to pH 3 with glacial acetic acid and applied to octadecylsilyl silica columns. The columns were washed with 15% aqueous ethanol followed by petroleum ether and then eluted with methyl formate. Methyl formate was dried (Speed Vac) and PGs reconstituted in PBS for radioimmunoassay (16, 31). The recovery of radioactive PGE2 and 6ketoPGF1alpha was >96%, and the interassay variability was <5%.

Chemicals

The following compounds were used: celecoxib (mol wt 381.4) and SC309A (a prodrug of celecoxib, mol wt 459.4; G. D. Searle, Skokie, IL), indomethacin (Sigma), NS398 (Cayman Chemical, Ann Arbor, MI), and a radioimmunoassay kit for PGE2 and 6ketoPGF1alpha (Advanced Magnetics, Boston, MA).

For the in vitro studies, indomethacin was prepared in ethanol (42 × 10-3 M). Both NS398 (51 × 10-3 M) and celecoxib (53 × 10-3 M) were prepared in DMSO. The final concentration of ethanol or DMSO in the bath solution did not affect tissue contractility. All other compounds were dissolved directly in Krebs solution.

Statistics

Statistical analyses were performed by the appropriate Student's t-test and by analysis of variance. Scheffé's test was used for post hoc analyses. Nonparametric data were compared with Wilcoxon's signed-rank test. Values are expressed as means ± SD. Drug doses refer to their final molar concentration in the bath.


    RESULTS
TOP
ABSTRACT
INTRODUCTION
METHODS
RESULTS
DISCUSSION
REFERENCES

In Vitro Studies

In the presence of 30% O2, rings of ductus arteriosus contracted to a tension that was ~30% of the rings' net active tension (Fig. 2). The nonselective COX inhibitor indomethacin caused an additional dose-dependent increase in tension (Fig. 2C). Both COX-2 inhibitors celecoxib and NS398 caused dose-dependent increases in ductus tension at concentrations that were specific for COX-2 (14, 19, 23, 30, 33, 34). At the highest concentrations tested, the contraction caused by celecoxib (5 × 10-6 M) was 51% of that caused by NS398 (5 × 10-6 M). After the contractions induced by the selective COX-2 inhibitors, indomethacin produced an additional significant (P < 0.01) increase in tension (Fig. 2, A and B). SC309A, the prodrug of celecoxib, had no effect on ductus tension at concentrations of 1, 10, or 50 µg/ml (2.2, 22, or 109 × 10-6 M, respectively) (n = 4).


View larger version (27K):
[in this window]
[in a new window]
  		Fig. 2.   Inhibitors of cyclooxygenase (COX) contract fetal lamb ductus arteriosus. Ductus rings were incubated in 30% oxygen. Each ring was exposed to increasing concentrations of either celecoxib or NS398 (COX-2 inhibitors) or nonselective COX inhibitor indomethacin (Indo). Maximal tension was determined with 100 mM KCl-Krebs solution (K+); minimal tension was determined with 10-4 M sodium nitroprusside (SNP). All tensions were expressed as percent net active tension (means ± SD). Net active tension is measured in grams. Starting tensions: 6 ± 1 (A), 6 ± 1 (B), and 5 ± 2 g (C). Ring weight: 41 ± 9 (A), 55 ± 27 (B), and 57 ± 29 mg (C). * P < 0.01, COX-inhibitor-induced tension vs. O2-induced tension.

Both the nonselective COX inhibitor indomethacin and the selective COX-2 inhibitors celecoxib and NS398 decreased the rate of release of PGE2 and the stable metabolite of prostacyclin, 6ketoPGF1alpha , into the surrounding bath solution (Fig. 3). After the reduction in PGE2 and 6ketoPGF1alpha release by the two COX-2 inhibitors, indomethacin produced a further reduction in the release of both PGs (P < 0.05; Fig. 3). The changes in PG release paralleled the changes we saw in ductus tension (Figs. 2 and 3).


View larger version (29K):
[in this window]
[in a new window]
  		Fig. 3.   PGE2 and 6ketoPGF1alpha production by rings of ductus arteriosus. Height of columns represents means ± SD immunoreactive PGE2 or 6ketoPGF1alpha released into a 10-ml bath during 40-min incubation period per 100 mg tissue weight. Rings were incubated in 30% oxygen with or without following inhibitors: celecoxib, NS398, and Indo. Ring weight, 48 ± 20 mg; starting tension, 6 ± 1 g. Dashed lines represent limit of detection in assay. * P < 0.05, COX inhibitor vs. control condition.

In Vivo Studies

Before starting drug infusions, the baseline fetal hemodynamic variables, systemic arterial blood gases, pH, lactate, and glucose concentrations were similar among the three study groups [indomethacin (Table 1); low-dose SC309A/celecoxib (Table 2); high-dose SC309A/celecoxib (Table 3)]. These variables were within the accepted range for our laboratory. Normal saline or 50 mM Tris-HCl (pH 8 buffer) were infused (10 ml/h) into a separate group of nine fetuses for 5 h to study the effects of the infusion protocols on the fetus; there were no significant changes in any of the hemodynamic or metabolic variables during either infusion (data not shown).

                              
View this table:
[in this window]
[in a new window]
  		Table 1.   Hemodynamic changes in indomethacin-treated lamb fetuses


                              
View this table:
[in this window]
[in a new window]
  		Table 2.   Hemodynamic changes in SC309A/celecoxib-treated lamb fetuses (low concentration range)


                              
View this table:
[in this window]
[in a new window]
  		Table 3.   Hemodynamic changes in SC309A/celecoxib-treated lamb fetuses (high concentration range)

In the indomethacin-treated fetuses, ductus arteriosus blood flow decreased during the first hour of the infusion, but returned toward baseline over the next 3 h (Table 1). The pressure gradient and calculated resistance across the ductus increased within 15 min of starting the infusion (data not shown) and persisted throughout the infusion (Table 1). There was a significant increase in lactate and decrease in pH during the indomethacin infusion. These findings are similar to previous reports (13).

Continuous infusions of the prodrug SC309A produced a gradual increase in plasma celecoxib concentrations (Fig. 4); by 1 h of infusion, celecoxib concentrations had only reached 66% of the desired low dose and high dose concentrations. Because of the delay in reaching the desired celecoxib concentrations, the infusion and measurements were continued 1 h longer than the indomethacin experiments. During the infusions, maximal concentrations of the prodrug SC309A were 51 ± 19 (110 ± 41 × 10-6 M) and 25 ± 6 µg/ml (54 ± 13 × 10-6 M) in the high and low dose groups, respectively.


View larger version (22K):
[in this window]
[in a new window]
  		Fig. 4.   Fetal plasma concentrations of celecoxib. Prodrug SC309A was continuously infused into fetal vein at 31 ± 8 (high-dose animals) or 19 ± 5 mg · kg-1 · h-1 (Low-dose animals) after a priming dose (given over 10 min) of 31 or 19 mg/kg, respectively. A: plasma concentrations of celecoxib at 30 min and 1, 2, 3, 4, and 5 h during the continuous infusion (means ± SD). B: maximum, average, and minimum plasma concentrations of celecoxib after first 60 min of each infusion rate.

At high concentrations of celecoxib, there was a small, transient drop in ductus flow, which returned toward baseline by the end of the infusion (Fig. 5). On the other hand, there was a sustained increase in the pressure gradient and resistance across the ductus that persisted throughout the infusion (Table 3). The maximum increases in pressure gradient and resistance at the higher concentrations were not significantly different from those reached during the indomethacin infusions (Fig. 5). The fetuses also developed a progressive drop in blood pH associated with an increase in PaCO2 and lactate (Table 3).Even at low concentrations, celecoxib produced a significant increase in pressure gradient and resistance across the ductus that persisted throughout the infusion in five of the six fetuses (Table 2; Fig. 5). There were no sustained changes in pH or lactate during the low dose celecoxib infusions. Indomethacin lowered circulating concentrations of PGE2 and 6ketoPGF1alpha by 50 ± 33% and 66 ± 29%, respectively. The minimum concentration was reached 2.1 ± 0.7 h after starting the infusion. Celecoxib also lowered circulating concentrations of PGE2 and 6ketoPGF1alpha (Fig. 6). Celecoxib lowered plasma PGE2 concentrations by 37 ± 11% (high concentration) and 46 ± 20% (low concentration); 6ketoPGF1alpha concentrations were reduced by 60 ± 20% (high concentration) and 60 ± 28% (low concentration). The time to reach the minimum concentration of either PGE2 or 6ketoPGF1alpha was 3.2 ± 1.3 h in the low concentration group and 2.3 ± 12.3 h in the high concentration group.


View larger version (25K):
[in this window]
[in a new window]
  		Fig. 5.   Changes in ductus arteriosus resistance (A), mean pulmonary arterial pressure (mPAP)-to-mean systemic arterial pressure (mSAP) gradient (B), and ductus arteriosus blood flow (C) in fetal lambs infused with SC309A (celecoxib) or Indo. Values are means ± SD. Values reported in A and B are maximum values and in C, minimum values obtained during infusions. These are compared with preinfusion values. Celecoxib (low concentration), n = 6; celecoxib (high concentration), n = 7; Indo, n = 9. * P < 0.05, ** P < 0.01 vs. preinfusion values. Duration of infusion to reach maximum ductus resistance (A) were: celecoxib (low) = 125 ± 66 min, celecoxib (high) = 197 ± 75 min, and Indo = 118 ± 80 min; maximum pressure gradient (B) were: celecoxib (low) = 75 ± 41 min, celecoxib (high) = 163 ± 75 min, and Indo = 136 ± 77 min; minimum ductus blood flow (C) were: celecoxib (low) = 135 ± 116 min, celecoxib (high) = 167 ± 91 min, and Indo = 101 ± 77 min.



View larger version (19K):
[in this window]
[in a new window]
  		Fig. 6.   Fetal plasma concentrations of PGE2 and 6ketoPGF1alpha during high- and low-dose SC309A (celecoxib) infusions. Plasma concentrations of PGE2 and 6ketoPGF1alpha were obtained before (preinfusion) infusion and at hourly intervals during infusion of SC309A (celecoxib). Values are means ± SD. Minimum values of PGE2 and 6ketoPGF1alpha are compared with preinfusion values (* P < 0.05). Dashed lines represent limit of detection in assay.


    DISCUSSION
TOP
ABSTRACT
INTRODUCTION
METHODS
RESULTS
DISCUSSION
REFERENCES

We have shown previously that both COX-1 and -2 are expressed by the fetal lamb ductus arteriosus and play a role in regulating ductus contractility in vitro (3). In the present study, we investigated the actions of two selective COX-2 inhibitors, celecoxib and NS398, and compared them to the nonselective inhibitor indomethacin. NS398 and celecoxib decreased PG production and produced a significant increase in tension in isolated rings of lamb ductus arteriosus at concentrations that are specific for COX-2 (Figs. 2 and 3) (14, 19, 33, 34). Whether endogenous PGs, made by the ductus arteriosus, are solely responsible for its regulation in vivo is still unclear. Circulating PGs in the fetus are markedly elevated compared with the newborn or adult (5) and may contribute to in vivo patency. We found that celecoxib concentrations that normally are achieved during the treatment of arthritis and that are specific for COX-2 (33) also decreased fetal plasma concentrations of PGs (Fig. 6) and produced significant constriction of the fetal lamb ductus in vivo (Tables 2 and 3; Fig. 5). However, despite a similar reduction in circulating PG levels in both celecoxib- and indomethacin-treated fetuses, indomethacin tended to have a greater effect on ductus closure in vivo (see below); this may suggest a role for locally produced PGs in regulating ductus tone. Whereas these findings do not clarify whether circulating PGs are more or less important than locally produced PGs, they do point out that COX-2 has an important role in vasoregulation of the fetal ductus arteriosus in vivo.

In our in vivo studies, an inactive prodrug of celecoxib (SC309A) was used to achieve the desired circulating concentrations of celecoxib. It is unlikely that SC309A was responsible for the ductus constriction, because SC309A had no effect on ductus tone in vitro. It is possible that the importance of COX-2, in maintaining ductus patency in vivo, might have been overestimated by our experimental model. Injury of the vessel wall during surgical placement of the ultrasonic flow transducer might have induced COX-2 overexpression that would not normally be present in the uninstrumented ductus (21, 22). However, this explanation would not account for our former immunohistochemical and biochemical observations (3) or our current in vitro results (Figs. 2 and 3). To address this issue specifically, we performed a separate series of experiments in three fetuses (128 ± 1 day gestation) in which no flow transducers were used (data not shown). Catheters were placed in the pulmonary trunk and systemic artery, avoiding the ductus. High concentrations of celecoxib produced the same maximal pressure gradient across the ductus (10.5 ± 0.7 mmHg) as seen in our study animals (Fig. 5B). Therefore, it appears that COX-2 exerts a significant contribution to PG formation and vasomotor tone in the ductus in vivo as well as in vitro.

Indomethacin, a nonselective inhibitor of COX-1 and -2, produced a significantly greater inhibition of endogenous PG production (Fig. 3) and a significantly greater increase in ductus tone in vitro (Fig. 2) than did the selective COX-2 inhibitors. These results are similar to results we previously have published (3). Similarly, indomethacin produced a significantly greater fall in ductus blood flow in vivo. Although the difference did not reach statistical significance, indomethacin also tended to have a greater effect on ductus resistance when compared with celecoxib (Fig. 5). These findings are consistent with both COX-1 and -2 having important functions in ductus arteriosus vasoregulation (3).

During the indomethacin infusions, fetuses frequently developed a lactic acidosis (Table 1). The etiology of this is unclear; it does not appear to be due to ductus constriction, because indomethacin still produces a lactic acidosis even after the ductus wall has been infiltrated with Formalin, making constriction impossible (data not shown). High concentrations of celecoxib also caused a lactic acidosis (Table 3). This was not observed in the low celecoxib concentration group.Whether celecoxib will have less constrictive effects on the ductus and will be less likely to produce lactic acidosis than indomethacin, in clinical practice, will depend on the drug levels needed to achieve equivalent effects. Even at low celecoxib concentrations, fetuses may still develop a lactic acidosis; in preliminary studies, we have seen a marked metabolic acidosis develop if fetuses were hemodynamically compromised before the administration of low concentrations of celecoxib (data not shown).

Perspectives

At this time, it is premature to extrapolate our in vivo results to the human fetus. In rats, celecoxib crosses the placenta; fetal concentrations are similar to maternal concentrations (data not shown). However, celecoxib's pharmacokinetic profile in the human fetus is unknown. In addition, fetuses in our experimental model were exposed to maximal drug levels for longer durations than would be expected from the dosing regimens used in the clinical trials. The current findings also may represent a species-specific expression of COX-2 that is unique to the fetal lamb ductus. We have previously shown that COX-2 expression is very low in the fetal pig ductus (although a high level of expression was found in the neonatal ductus of the pig). No data are available currently for the human ductus. We have recently found that another fetal primate, the baboon, expresses COX-1 and -2 in its ductus in amounts and distribution that are similar to what we have observed in the fetal lamb (R. I. Clyman and S. Seidner, unpublished results). Until further studies are available, we feel that caution should be used when recommending COX-2 inhibitors for use in pregnant women (32).


    ACKNOWLEDGEMENTS

The authors thank Paul Sagan for expert editorial assistance, Hensy Fernandez and Yao Qi Chen for technical assistance, and Mario Trujillo for help in obtaining tissue specimens.


    FOOTNOTES

This work was supported in part by United States Public Health Service and National Institutes of Health Grants HL-46691, HL-56061, and HD-32518, a gift from the Perinatal Associates Research Foundation, a grant from the Medical Research Council of Canada, and a grant from Searle Laboratories.

The costs of publication of this article were defrayed in part by the payment of page charges. The article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. §1734 solely to indicate this fact.

Address for reprint requests and other correspondence: R. I. Clyman, Box 0544, HSE 1492, Univ. of California, San Francisco, San Francisco, CA 941430-0544.

Received 25 May 1999; accepted in final form 18 December 1999.


    REFERENCES
TOP
ABSTRACT
INTRODUCTION
METHODS
RESULTS
DISCUSSION
REFERENCES

1.   Brash, AR, Hickey DE, Graham TP, Oates JA, and Cotton RB. Pharmacokinetics of indomethacin in the neonate. N Engl J Med 305: 67-72, 1981[Abstract].

2.   Chan, C-C, Boyce S, Brideau C, Ford-Hutchinson AW, Gordon R, Guay D, Hill RG, Li CS, Mancini J, and Penneton M. Pharmacology of a selective cyclooxygenase-2 inhibitor, L-745,337: a novel nonsteroidal anti-inflammatory agent with an ulcerogenic sparing effect in rat and nonhuman primate stomach. J Pharmacol Exp Ther 274: 1531-1537, 1995[Abstract/Free Full Text].

3.   Clyman, RI, Hardy P, Waleh N, Chen YQ, Mauray F, Fouron J-C, and Chemtob S. Cyclooxygenase-2 plays a significant role in regulating the tone of the fetal lamb ductus arteriosus. Am J Physiol Regulatory Integrative Comp Physiol 276: R913-R921, 1999[Abstract/Free Full Text].

4.   Clyman, RI, Mauray F, Roman C, and Rudolph AM. PGE2 is a more potent vasodilator of the lamb ductus arteriosus than either PGI2 or 6 keto PGF1alpha . Prostaglandins 16: 259-264, 1978[ISI][Medline].

5.   Clyman, RI, Mauray F, Roman C, Rudolph AM, and Heymann MA. Circulating prostaglandin E2 concentrations and patent ductus arteriosus in fetal and neonatal lambs. J Pediatr 97: 455-461, 1980[ISI][Medline].

6.   Clyman, RI, Mauray F, Wong L, Heymann MA, and Rudolph AM. The developmental response of the ductus arteriosus to oxygen. Biol Neonate 34: 177-181, 1978[ISI][Medline].

7.   Clyman, RI, Saugstad OD, and Mauray F. Reactive oxygen metabolites relax the lamb ductus arteriosus by stimulating prostaglandin production. Circ Res 64: 1-8, 1989[Abstract/Free Full Text].

8.   Coceani, F, and Olley PM. The response of the ductus arteriosus to prostaglandins. Can J Physiol Pharmacol 51: 220-225, 1973[ISI][Medline].

10.   Eronen, M. The hemodynamic effects of antenatal indomethacin and a beta-sympathomimetic agent on the fetus and the newborn: a randomized study. Pediatr Res 33: 615-619, 1993[ISI][Medline].

11.   Eronen, M, Pesonen E, Kurki T, Ylikorkala O, and Hallman M. The effects of indomethacin and a beta-sympathomimetic agent on the fetal ductus arteriosus during treatment of premature labor: a randomized double-blind study. Am J Obstet Gynecol 164: 141-146, 1991[ISI][Medline].

12.   Fineman, JR, Takahashi Y, Roman C, and Clyman RI. Endothelin-receptor blockade does not alter closure of the ductus arteriosus. Am J Physiol Heart Circ Physiol 275: H1620-H1626, 1998[Abstract/Free Full Text].

13.   Fox, JJ, Ziegler JW, Dunbar DI, Halbower AC, Kinsella JP, and Abman SH. Role of nitric oxide and cGMP system in regulation of ductus arteriosus tone in ovine fetus. Am J Physiol Heart Circ Physiol 271: H2638-H2645, 1996[Abstract/Free Full Text].

14.   Futaki, N, Yoshikawa K, Hamasaka Y, Arai I, Higuchi S, Iizuka H, and Otomo S. NS-398, a novel non-steroidal anti-inflammatory drug with potent analgesic and antipyretic effects, which causes minimal stomach lesions. Gen Pharmacol 24: 105-110, 1993[ISI][Medline].

15.   Gans, KR, Galbraith W, Roman RJ, Haber SB, Kerr JS, Schmidt WK, Smith C, Hewes WE, and Ackerman NR. Anti-inflammatory and safety profile of DuP 697, a novel orally effective prostaglandin synthesis inhibitor. J Pharmacol Exp Ther 254: 180-187, 1990[Abstract/Free Full Text].

16.   Hanna, N, Peri KG, Abran D, Hardy P, Doke A, Lachapelle P, Roy MS, Orquin J, Varma DR, and Chemtob S. Light induces peroxidation in retina by activating prostaglandin G/H synthase. Free Radic Biol Med 23: 885-897, 1997[ISI][Medline].

17.   Heymann, MA, and Rudolph AM. Control of the ductus arteriosus. Physiol Rev 55: 62-78, 1975[Abstract/Free Full Text].

18.   Hirst, JJ, Teixeira FJ, Zakar T, and Olson DM. Prostaglandin endoperoxide-H synthase-1 and -2 messenger ribonucleic acid levels in human amnion with spontaneous labor onset. J Clin Endocrinol Metab 80: 517-523, 1995[Abstract].

19.   Johnson, JL, Wimsatt J, Buckel SD, Dyer RD, and Maddipati KR. Purification and characterization of prostaglandin H synthase-2 from sheep placental cotyledons. Arch Biochem Biophys 324: 26-34, 1995[ISI][Medline].

20.   Langenbach, R, Morham SG, Tiano HF, Loftin CD, Ghanayem BI, Chulada PC, Mahler JF, and Lee CA. Disruption of the mouse cyclooxygenase 1 gene. Characteristics of the mutant and areas of future study. Adv Exp Med Biol 407: 87-92, 1997[ISI][Medline].

21.   Lee, SH, Soyoola E, Chanmugam P, Hart S, Sun W, Zhong H, Liou S, Simmons D, and Hwang D. Selective expression of mitogen-inducible cyclooxygenase in macrophages stimulated with lipopolysaccharide. J Biol Chem 267: 25934-25938, 1992[Abstract/Free Full Text].

22.   Maier, JA, Hla T, and Maciag T. Cyclooxygenase is an immediate-early gene induced by interleukin-1 in human endothelial cells. J Biol Chem 265: 10805-10808, 1990[Abstract/Free Full Text].

23.   Meade, EA, Smith WL, and DeWitt DL. Differential inhibition of prostaglandin endoperoxide synthase (cyclooxygenase) isozymes by aspirin and other non-steroidal anti-inflammatory drugs. J Biol Chem 268: 6610-6614, 1993[Abstract/Free Full Text].

24.   Meyers, RL, Alpan G, Lin E, and Clyman RI. Patent ductus arteriosus, indomethacin, and intestinal distension: effects on intestinal blood flow and oxygen consumption. Pediatr Res 29: 569-574, 1991[ISI][Medline].

25.   Moise, KJ, Jr, Huhta JC, Sharif DS, Ou CN, Kirshon B, Wasserstrum N, and Cano L. Indomethacin in the treatment of preterm labor: effects on the fetal ductus. N Engl J Med 319: 327-331, 1988[Abstract].

26.   Moise, KJ, Ou-N C, Kirshon B, Cano LE, Rognerud C, and Carpenter RJ. Placental transfer of indomethacin in the human pregnancy. Obstet Gynecol 162: 549-554, 1990.

27.   Momma, K, Hagiwara H, and Konishi T. Constriction of fetal ductus arteriosus by non-steroidal anti-inflammatory drugs: study of additional 34 drugs. Prostaglandins 28: 527-536, 1984[ISI][Medline].

27a.   Morham, SG, Langenbach R, Mahler J, and Smithies O. Characterization of prostaglandin H synthase 2 deficient mice and implications for mechanisms of NSAID action. Adv Exp Med Biol 407: 131-138, 1997[ISI][Medline].

28.   O'Neill, GP, and Ford-Hutchinson AW. Expression of mRNA for cyclooxygenase-1 and cyclooxygenase-2 in human tissues. FEBS Lett 330: 156-160, 1993[ISI][Medline].

29.   Pace-Asciak, CR, and Rangaraj G. Prostaglandin biosynthesis and catabolism in the lamb ductus arteriosus, aorta and pulmonary artery. Biochim Biophys Acta 529: 13-20, 1978[Medline].

30.   Penning, TD, Talley JJ, Bertenshaw SR, Carter JS, Collins PW, Docter S, Graneto MJ, Lee LF, Malecha JW, Miyashiro JM, Rogers RS, Rogier DJ, Yu SS, Anderson GD, Burton EG, Cogburn JN, Gregory SA, Koboldt CM, Perkins WE, Seibert K, Veenhuizen AW, Zhang YY, and Isakson PC. Synthesis and biological evaluation of the 1,5-diarylpyrazole class of cyclooxygenase-2 inhibitors: identification of 4-[5-(4-methylphenyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl]benzenesulfonamide (SC-58635, celecoxib). J Med Chem 40: 1347-1365, 1997[ISI][Medline].

31.   Peri, KG, Hardy P, Li DY, Varma DR, and Chemtob S. Prostaglandin G/H synthase-2 is a major contributor of brain prostaglandins in the newborn. J Biol Chem 270: 24615-24620, 1995[Abstract/Free Full Text].

32.   Sawdy, R, Slater D, Fisk N, Edmonds DK, and Bennett P. Use of a cyclo-oxygenase type-2-selective non-steroidal anti-inflammatory agent to prevent preterm delivery. Lancet 350: 265-266, 1997[ISI][Medline].

33.   Simon, LS, Lanza FL, Lipsky PE, Hubbard RC, Talwalker S, Schwartz BD, Isakson PC, and Geis GS. Preliminary study of the safety and efficacy of SC-58635, a novel cyclooxygenase 2 inhibitor: efficacy and safety in two placebo-controlled trials in osteoarthritis and rheumatoid arthritis, and studies of gastrointestinal and platelet effects. Arthritis Rheum 41: 1591-1602, 1998[ISI][Medline].

34.   Smith, CJ, Zhang Y, Koboldt CM, Muhammad J, Zweifel BS, Shaffer A, Talley JJ, Masferrer JL, Seibert K, and Isakson PC. Pharmacological analysis of cyclooxygenase-1 in inflammation. Proc Natl Acad Sci USA 95: 13313-13318, 1998[Abstract/Free Full Text].

35.   Van den Veyver, IB, Moise KJ, Jr, Ou CN, and Carpenter RJ, Jr. The effect of gestational age and fetal indomethacin levels on the incidence of constriction of the fetal ductus arteriosus. J Obstet Gynecol 82: 500-503, 1993.

36.   Vane, J. Towards a better aspirin. Nature 367: 215-216, 1994[Medline].

37.   Vermillion, ST, Scardo JA, Lashus AG, and Wiles HB. The effect of indomethacin tocolysis on fetal ductus arteriosus constriction with advancing gestational age. Am J Obstet Gynecol 177: 256-261, 1997[ISI][Medline].

Am J Physiol Regul Integr Comp Physiol 278(6):R1496-R1505
0363-6119/00 $5.00 Copyright © 2000 the American Physiological Society


This article has been cited by other articles:


Home page
 Am. J. Physiol. Regul. Integr. Comp. Physiol.Home page
P. Agren, A. L. Cogolludo, C. G. A. Kessels, F. Perez-Vizcaino, J. G. R. De Mey, C. E. Blanco, and E. Villamor
Ontogeny of chicken ductus arteriosus response to oxygen and vasoconstrictors
Am J Physiol Regulatory Integrative Comp Physiol, January 1, 2007; 292(1): R485 - R496.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
H. E. Zeytin, A. C. Patel, C. J. Rogers, D. Canter, S. D. Hursting, J. Schlom, and J. W. Greiner
Combination of a Poxvirus-Based Vaccine with a Cyclooxygenase-2 Inhibitor (Celecoxib) Elicits Antitumor Immunity and Long-Term Survival in CEA.Tg/MIN Mice
Cancer Res., May 15, 2004; 64(10): 3668 - 3678.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Physiol. Regul. Integr. Comp. Physiol.Home page
A. Bouayad, J.-C. Fouron, X. Hou, M. Beauchamp, C. Quiniou, D. Abran, K. Peri, R. I. Clyman, D. R. Varma, and S. Chemtob
Developmental regulation of prostaglandin E2 synthase in porcine ductus arteriosus
Am J Physiol Regulatory Integrative Comp Physiol, May 1, 2004; 286(5): R903 - R909.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Physiol. Regul. Integr. Comp. Physiol.Home page
J. P. Granger
Maternal and fetal adaptations during pregnancy: lessons in regulatory and integrative physiology
Am J Physiol Regulatory Integrative Comp Physiol, December 1, 2002; 283(6): R1289 - R1292.
[Full Text] [PDF]

Home page
 LupusHome page
E N Harris
Antirheumatic drugs in pregnancy
Lupus, October 1, 2002; 11(10): 683 - 689.
[PDF]

Home page
 Am. J. Physiol. Regul. Integr. Comp. Physiol.Home page
H. Ehmke
Developmental physiology of the cardiovascular system
Am J Physiol Regulatory Integrative Comp Physiol, February 1, 2002; 282(2): R331 - R333.
[Full Text] [PDF]

Home page
 Am. J. Physiol. Regul. Integr. Comp. Physiol.Home page
D. H. Wright, D. Abran, M. Bhattacharya, X. Hou, S. G. Bernier, A. Bouayad, J.-C. Fouron, A. Vazquez-Tello, M. H. Beauchamp, R. I. Clyman, et al.
Prostanoid receptors: ontogeny and implications in vascular physiology
Am J Physiol Regulatory Integrative Comp Physiol, November 1, 2001; 281(5): R1343 - R1360.
[Abstract] [Full Text] [PDF]

Home page
 Annals of Clinical & Laboratory ScienceHome page
E. Fosslien
Molecular Pathology of Cyclooxygenase-2 in Cancer-induced Angiogenesis
Ann. Clin. Lab. Sci., October 1, 2001; 31(4): 325 - 348.
[Abstract] [Full Text] [PDF]

Home page
 Mol Hum ReprodHome page
M. Sakai, K. Tanebe, Y. Sasaki, K. Momma, S. Yoneda, and S. Saito
Evaluation of the tocolytic effect of a selective cyclooxygenase-2 inhibitor in a mouse model of lipopolysaccharide-induced preterm delivery
Mol. Hum. Reprod., June 1, 2001; 7(6): 595 - 602.
[Abstract] [Full Text] [PDF]

This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow A corrigendum has been published
Right arrow A corrigendum has been published
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow